T CELL RECEPTORS

T CELL RECEPTORS

The present invention relates to T cell receptors (TCRs) that bind the HLA-A*02 restricted peptide GVYDGREHTV (SEQ ID NO: 1) derived from the germline cancer antigen MAGE A4. Said TCRs may comprise non-natural mutations within the alpha and/or beta variable domains relative to a native MAGE A4 TCR....

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: MAHON Tara, HAYES Conor, HIBBERT Linda, RAMAN Marine, LIDDY Nathaniel
Format: Patent
Sprache:eng ; slv
Schlagworte:
CHEMISTRY
METALLURGY
ORGANIC CHEMISTRY
PEPTIDES
Online-Zugang:Volltext bestellen
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page
container_issue
container_start_page
container_title
container_volume
creator MAHON Tara
HAYES Conor
HIBBERT Linda
RAMAN Marine
LIDDY Nathaniel
description The present invention relates to T cell receptors (TCRs) that bind the HLA-A*02 restricted peptide GVYDGREHTV (SEQ ID NO: 1) derived from the germline cancer antigen MAGE A4. Said TCRs may comprise non-natural mutations within the alpha and/or beta variable domains relative to a native MAGE A4 TCR. The TCRs of the invention are particularly suitable for use as novel immunotherapeutic reagents for the treatment of malignant disease
format Patent
fullrecord <record><control><sourceid>epo_EVB</sourceid><recordid>TN_cdi_epo_espacenet_SI3440105TT1</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>SI3440105TT1</sourcerecordid><originalsourceid>FETCH-epo_espacenet_SI3440105TT13</originalsourceid><addsrcrecordid>eNrjZBAIUXB29fFRCHJ1dg0I8Q8K5mFgTUvMKU7lhdLcDIpuriHOHrqpBfnxqcUFicmpeakl8cGexiYmBoYGpiEhhsbEqAEAAAAdyg</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>patent</recordtype></control><display><type>patent</type><title>T CELL RECEPTORS</title><source>esp@cenet</source><creator>MAHON Tara ; HAYES Conor ; HIBBERT Linda ; RAMAN Marine ; LIDDY Nathaniel</creator><creatorcontrib>MAHON Tara ; HAYES Conor ; HIBBERT Linda ; RAMAN Marine ; LIDDY Nathaniel</creatorcontrib><description>The present invention relates to T cell receptors (TCRs) that bind the HLA-A*02 restricted peptide GVYDGREHTV (SEQ ID NO: 1) derived from the germline cancer antigen MAGE A4. Said TCRs may comprise non-natural mutations within the alpha and/or beta variable domains relative to a native MAGE A4 TCR. The TCRs of the invention are particularly suitable for use as novel immunotherapeutic reagents for the treatment of malignant disease</description><language>eng ; slv</language><subject>CHEMISTRY ; METALLURGY ; ORGANIC CHEMISTRY ; PEPTIDES</subject><creationdate>2022</creationdate><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&amp;date=20220729&amp;DB=EPODOC&amp;CC=SI&amp;NR=3440105T1$$EHTML$$P50$$Gepo$$Hfree_for_read</linktohtml><link.rule.ids>230,308,776,881,25542,76290</link.rule.ids><linktorsrc>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&amp;date=20220729&amp;DB=EPODOC&amp;CC=SI&amp;NR=3440105T1$$EView_record_in_European_Patent_Office$$FView_record_in_$$GEuropean_Patent_Office$$Hfree_for_read</linktorsrc></links><search><creatorcontrib>MAHON Tara</creatorcontrib><creatorcontrib>HAYES Conor</creatorcontrib><creatorcontrib>HIBBERT Linda</creatorcontrib><creatorcontrib>RAMAN Marine</creatorcontrib><creatorcontrib>LIDDY Nathaniel</creatorcontrib><title>T CELL RECEPTORS</title><description>The present invention relates to T cell receptors (TCRs) that bind the HLA-A*02 restricted peptide GVYDGREHTV (SEQ ID NO: 1) derived from the germline cancer antigen MAGE A4. Said TCRs may comprise non-natural mutations within the alpha and/or beta variable domains relative to a native MAGE A4 TCR. The TCRs of the invention are particularly suitable for use as novel immunotherapeutic reagents for the treatment of malignant disease</description><subject>CHEMISTRY</subject><subject>METALLURGY</subject><subject>ORGANIC CHEMISTRY</subject><subject>PEPTIDES</subject><fulltext>true</fulltext><rsrctype>patent</rsrctype><creationdate>2022</creationdate><recordtype>patent</recordtype><sourceid>EVB</sourceid><recordid>eNrjZBAIUXB29fFRCHJ1dg0I8Q8K5mFgTUvMKU7lhdLcDIpuriHOHrqpBfnxqcUFicmpeakl8cGexiYmBoYGpiEhhsbEqAEAAAAdyg</recordid><startdate>20220729</startdate><enddate>20220729</enddate><creator>MAHON Tara</creator><creator>HAYES Conor</creator><creator>HIBBERT Linda</creator><creator>RAMAN Marine</creator><creator>LIDDY Nathaniel</creator><scope>EVB</scope></search><sort><creationdate>20220729</creationdate><title>T CELL RECEPTORS</title><author>MAHON Tara ; HAYES Conor ; HIBBERT Linda ; RAMAN Marine ; LIDDY Nathaniel</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-epo_espacenet_SI3440105TT13</frbrgroupid><rsrctype>patents</rsrctype><prefilter>patents</prefilter><language>eng ; slv</language><creationdate>2022</creationdate><topic>CHEMISTRY</topic><topic>METALLURGY</topic><topic>ORGANIC CHEMISTRY</topic><topic>PEPTIDES</topic><toplevel>online_resources</toplevel><creatorcontrib>MAHON Tara</creatorcontrib><creatorcontrib>HAYES Conor</creatorcontrib><creatorcontrib>HIBBERT Linda</creatorcontrib><creatorcontrib>RAMAN Marine</creatorcontrib><creatorcontrib>LIDDY Nathaniel</creatorcontrib><collection>esp@cenet</collection></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext_linktorsrc</fulltext></delivery><addata><au>MAHON Tara</au><au>HAYES Conor</au><au>HIBBERT Linda</au><au>RAMAN Marine</au><au>LIDDY Nathaniel</au><format>patent</format><genre>patent</genre><ristype>GEN</ristype><title>T CELL RECEPTORS</title><date>2022-07-29</date><risdate>2022</risdate><abstract>The present invention relates to T cell receptors (TCRs) that bind the HLA-A*02 restricted peptide GVYDGREHTV (SEQ ID NO: 1) derived from the germline cancer antigen MAGE A4. Said TCRs may comprise non-natural mutations within the alpha and/or beta variable domains relative to a native MAGE A4 TCR. The TCRs of the invention are particularly suitable for use as novel immunotherapeutic reagents for the treatment of malignant disease</abstract><oa>free_for_read</oa></addata></record>
fulltext fulltext_linktorsrc
identifier
ispartof
issn
language eng ; slv
recordid cdi_epo_espacenet_SI3440105TT1
source esp@cenet
subjects CHEMISTRY
METALLURGY
ORGANIC CHEMISTRY
PEPTIDES
title T CELL RECEPTORS
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-30T09%3A40%3A54IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-epo_EVB&rft_val_fmt=info:ofi/fmt:kev:mtx:patent&rft.genre=patent&rft.au=MAHON%20Tara&rft.date=2022-07-29&rft_id=info:doi/&rft_dat=%3Cepo_EVB%3ESI3440105TT1%3C/epo_EVB%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/&rfr_iscdi=true